← Leaderboards
Song Yao
Kaiser Foundation Research Institute
$11,329,919
Attributed
$29,600,617
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2012–25$10M$7.5M$5M$2.5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,600,617 · 9
By mechanism
R01$19,985,191 · 5
UH3$7,201,689 · 1
UG3$2,064,137 · 1
R03$349,600 · 2
Top collaborators
- Charles Stewart Kamen7 shared
- Christine B. Ambrosone6 shared
- Scott I. Abrams5 shared
- John David Carpten5 shared
- Julie R Palmer5 shared
- Wei Zheng5 shared
- Scarlett L Gomez4 shared
- Lawrence H Kushi4 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Lawrence H Kushi$60,993,337
- Erin Elizabeth Hahn$7,456,765
- Reina Haque$5,883,468
- Carlos Iribarren$8,324,626
- Bette J Caan$23,657,335
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorWomanMalignant Breast NeoplasmMortalityMalignant NeoplasmsPathway InteractionsGeneticGenesCancer TherapyEnrollmentImmune ResponseRisk FactorsDesignLife StyleBaseCharacteristicsMammary NeoplasmsTumor MicroenvironmentImmuneCancer Health DisparityRaceLinkCancer PatientEpidemiology
Grant awards (29)
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$2,425,687
UH3 · FY2025 · CA · contact PI
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$2,281,096
UH3 · FY2024 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$1,124,755
R01 · FY2024 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$735,428
R01 · FY2024 · CA · contact PI
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$2,494,906
UH3 · FY2023 · CA · contact PI
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women$1,291,552
R01 · FY2023 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$1,112,696
R01 · FY2023 · CA
Insights from Asian Populations into Disparities in Breast Cancer Prognosis and Outcomes$1,048,826
R01 · FY2023 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$815,928
R01 · FY2023 · CA · contact PI
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women$1,271,461
R01 · FY2022 · CA · contact PI
Insights from Asian Populations into Disparities in Breast Cancer Prognosis and Outcomes$1,031,487
R01 · FY2022 · CA
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$1,004,241
UG3 · FY2022 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$993,003
R01 · FY2022 · CA
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women$1,310,745
R01 · FY2021 · CA · contact PI
Insights from Asian Populations into Disparities in Breast Cancer Prognosis and Outcomes$1,067,902
R01 · FY2021 · CA
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$1,059,896
UG3 · FY2021 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$951,181
R01 · FY2021 · CA
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women$1,302,572
R01 · FY2020 · CA · contact PI
Insights from Asian Populations into Disparities in Breast Cancer Prognosis and Outcomes$1,145,972
R01 · FY2020 · CA
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$994,901
R01 · FY2020 · CA
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women$1,333,797
R01 · FY2019 · CA · contact PI
Genetic underpinnings of ethnic disparities in bone toxicities between Hispanic and non-Hispanic children treated for acute lymphoblastic leukemia$87,050
R03 · FY2019 · CA · contact PI
Genetic underpinnings of ethnic disparities in bone toxicities between Hispanic and non-Hispanic children treated for acute lymphoblastic leukemia$87,050
R03 · FY2018 · CA · contact PI
Exome Array Analysis of Reproductive Aging and Breast Cancer in African Americans$87,750
R03 · FY2016 · CA · contact PI
Lifestyle and Molecular Factors of Bone Health in Breast Cancer Survivors$625,919
R01 · FY2015 · CA
Exome Array Analysis of Reproductive Aging and Breast Cancer in African Americans$87,750
R03 · FY2015 · CA · contact PI
Lifestyle and Molecular Factors of Bone Health in Breast Cancer Survivors$615,578
R01 · FY2014 · CA
Lifestyle and Molecular Factors of Bone Health in Breast Cancer Survivors$500,071
R01 · FY2013 · CA
Lifestyle and Molecular Factors of Bone Health in Breast Cancer Survivors$711,417
R01 · FY2012 · CA